Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

The German Diabetes Society (DDG) issued a warning concerning a rise in pregnancies among women using injectable medications ...

From life-changing medical advancements to colorful auroras, this year has been packed with incredible science. It was hard ...

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution ...

This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.

Sol-Millennium® Medical Group, a leading manufacturer of medical devices, has launched an innovative needle-free injection ...

Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression The INHALE-1 study is a 26-week, ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Millions of diabetes patients have to take a painful insulin injection to keep sugar levels in control. Cipla is introducing ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

Cipla received approval from India's Central Drugs Standard Control Organisation to distribute and market Afrezza inhalation ...